Discover lung cancer biomarkers by integration of lung cancer secretome and malignant effusion proteome
碩士 === 長庚大學 === 臨床醫學研究所 === 98 === Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (80 %), which is one of the most prominent causes of cancer-related mortality worldwide. Discovery of serum tumor markers could facilitate early NSCLC detection and metastatic prognosis. Prot...
Main Authors: | Chih Liang Wang, 王智亮 |
---|---|
Other Authors: | J. S. Yu |
Format: | Others |
Published: |
2010
|
Online Access: | http://ndltd.ncl.edu.tw/handle/40459342875184297771 |
Similar Items
-
Development of a novel protein biomarker panel for lung cancer by integration of cancer cell secretome & pleural effusion proteome
by: Yu Ming Deng, et al.
Published: (2010) -
Discovering drug resistance-associated biomarkers from malignant pleural effusion of lung adenocarcinoma
by: Ien Chiuam Chiou, et al.
Published: (2018) -
Deep analysis of pleural effusion proteomes for lung cancer biomarkers discovery
by: Pei Jun Liu, et al.
Published: (2013) -
Potential Angiogenetic Biomarkers in Non-small Cell Lung Cancer with Malignant Pleural Effusion
by: I-Lin Hsu, et al.
Published: (2008) -
Advanced lung cancer presenting with malignant pericardial effusion
by: Abid M. Sadiq, et al.
Published: (2021-06-01)